Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Cost of Revenue (2016 - 2025)

Ani Pharmaceuticals' Cost of Revenue history spans 14 years, with the latest figure at $100.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 24.9% year-over-year to $100.3 million; the TTM value through Dec 2025 reached $341.3 million, up 36.41%, while the annual FY2025 figure was $341.3 million, 36.41% up from the prior year.
  • Cost of Revenue for Q4 2025 was $100.3 million at Ani Pharmaceuticals, up from $93.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $100.3 million in Q4 2025 and bottomed at $20.0 million in Q1 2021.
  • The 5-year median for Cost of Revenue is $45.2 million (2023), against an average of $50.6 million.
  • The largest annual shift saw Cost of Revenue dropped 8.34% in 2021 before it soared 71.48% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $33.9 million in 2021, then grew by 7.16% to $36.3 million in 2022, then soared by 47.06% to $53.4 million in 2023, then surged by 50.28% to $80.3 million in 2024, then rose by 24.9% to $100.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Cost of Revenue are $100.3 million (Q4 2025), $93.4 million (Q3 2025), and $74.6 million (Q2 2025).